Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel Reports First Quarter 2022 Financial Results
First Quarter Total Net Revenue of $36.1 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results
View HTML
Toggle Summary Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022
CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its first-quarter 2022 financial results and business
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Musculoskeletal Conference on March 22, 2022
CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Musculoskeletal Conference in
View HTML
Toggle Summary Vericel to Present at the Cowen 42nd Annual Health Care Conference on March 9, 2022
CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will participate in a fireside chat at the Cowen 42 nd Annual Health
View HTML
Toggle Summary Vericel Announces Appointment of Jonathan Siegal as Principal Accounting Officer
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Board of Directors has appointed Jonathan Siegal as the Company’s Principal Accounting Officer,
View HTML
Toggle Summary Vericel Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Full-Year 2022 Financial Guidance
Full-Year 2021 Total Revenue Growth of 26% Full-Year 2022 Total Revenue Guidance of $178 to $189 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and
View HTML
Toggle Summary Vericel to Report Fourth-Quarter 2021 Financial Results on February 24, 2022
CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter 2021 financial results and business
View HTML
Toggle Summary Vericel Announces Plans for a New State-of-the-Art Cell Therapy Manufacturing Facility to Support Long-Term Growth
CAMBRIDGE, Mass., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it has entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy
View HTML
Toggle Summary Vericel to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the 40 th Annual J.P.
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health and Services Forum on November 18th, 2021
CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.